UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
Debates & Insight Sponsored OMA at NICE: Unlocking Access One Year On A new report by health economist Leela Barham examines how NICE’s Office for Market Access has progressed after a year in operation.
Views & Analysis NICE’s Office for Market Access: is it unlocking value for p... Leela Barham considers how the OMA has progressed since its launch.
Views & Analysis Calls to end the silent epidemic of PTHP Campaigners want to raise awareness of post-traumatic hypopituitarism following a head injury.
Views & Analysis How can pharma help NHS improve mental health services? Sustainability and Transformation Plans present an opportunity for pharma to support research into mental health conditions.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
